Biomea Fusion, Inc. (BMEA)

NASDAQ: BMEA · Real-Time Price · USD

1.240

+0.020 (1.64%)

At close: Dec 31, 2025, 4:00 PM EST

1.210

-0.030 (-2.41%)

After-hours: Dec 31, 2025, 7:43 PM EST

Biomea Fusion Employees

Biomea Fusion had 106 employees as of December 31, 2024. The number of employees increased by 3 or 2.91% compared to the previous year.

Employees

106

Change (1Y)

3

Growth (1Y)

2.91%

Revenue / Employee

n/a

Profits / Employee

-$902,934

Market Cap

87.67M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	106	3	2.91%
Dec 31, 2023	103	20	24.10%
Dec 31, 2022	83	32	62.75%
Dec 31, 2021	51	39	325.00%
Dec 31, 2020	12	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

BMEA News

15 days ago - Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
22 days ago - Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - GlobeNewsWire
27 days ago - Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - GlobeNewsWire
4 weeks ago - Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - GlobeNewsWire
4 weeks ago - Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
5 weeks ago - Biomea Fusion to Participate at Upcoming Investor Conferences - GlobeNewsWire
7 weeks ago - Biomea Fusion to Participate at Jefferies London Healthcare Conference - GlobeNewsWire
2 months ago - Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025 - GlobeNewsWire